BioPharmSignal logoBioPharmSignal

Biotech News

Synlogic Announces Abstract Accepted for Poster Presentation at the International Conference on Microbiome Engineering 2023

Synlogic (SYBX)SynlogicConference / presentation

- Poster presentation on SYNB1353 program for homocystinuria includes findings from process improvements to improve activity of methionine degradation - CAMBRIDGE, Mass. , Dec. 07, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral,

Related news

NAMSNewAmsterdam Pharma2026-07-01 12:00 EST

NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026

BLTEBelite Bio2026-05-15 12:00 EST

Belite Bio Announces Oral Presentation at the 27th Fundus Disease Forum and International Retinal Symposium (Retina China 2026)

ALGSAligos Therapeutics2026-05-13 06:05 EST

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SGMTSagimet Biosciences2026-04-06 11:00 EST

Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

RYTMRhythm Pharmaceuticals2026-05-29 12:00 EST

Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026

CVRXCVRx2026-05-27 20:30 EST

CVRx to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

CVRXCVRx2026-05-20 20:30 EST

CVRx to Present at the William Blair 46th Annual Growth Stock Conference

NAMSNewAmsterdam Pharma2026-04-08 12:00 EST

NewAmsterdam Pharma to Present at the 25th Annual Needham Virtual Healthcare Conference

SGMTSagimet Biosciences2026-08-04 11:00 EST

Sagimet Biosciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

BLTEBelite Bio2026-04-27 12:00 EST

Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

View all latest news

Synlogic

Synlogic was a synthetic-biology company focused on engineered microbes and metabolic disease before its restructuring and decline. Its platform aimed to use living medicines to address rare disorders.

Recent company news

SYBXSynlogic2026-07-29 11:00 EST

Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement

SYBXSynlogic2024-11-12 21:35 EST

Synlogic Reports Third Quarter 2024 Financial Results

SYBXSynlogic2024-08-08 11:00 EST

Synlogic Reports Second Quarter 2024 Financial Results

SYBXSynlogic2024-05-14 11:00 EST

Synlogic Reports First Quarter 2024 Financial Results

SYBXSynlogic2024-03-19 11:00 EST

Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results

Stock data

Close
1.20 USD
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States